Ellsworth Advisors LLC Buys 4,112 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Ellsworth Advisors LLC grew its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 4.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 106,612 shares of the life sciences company’s stock after purchasing an additional 4,112 shares during the period. Integra LifeSciences comprises approximately 1.5% of Ellsworth Advisors LLC’s portfolio, making the stock its 18th biggest position. Ellsworth Advisors LLC owned about 0.14% of Integra LifeSciences worth $4,643,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. grew its holdings in shares of Integra LifeSciences by 469.5% in the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after acquiring an additional 615 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Integra LifeSciences in the third quarter valued at approximately $48,000. Covestor Ltd grew its holdings in shares of Integra LifeSciences by 63.0% in the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after acquiring an additional 602 shares in the last quarter. Captrust Financial Advisors lifted its stake in Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after purchasing an additional 976 shares during the last quarter. Finally, Coppell Advisory Solutions LLC purchased a new position in Integra LifeSciences in the second quarter valued at approximately $84,000. 84.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on IART. JMP Securities dropped their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 29th. StockNews.com upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Thursday. Truist Financial dropped their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research note on Friday, March 1st. Finally, Wells Fargo & Company upgraded Integra LifeSciences from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $40.00 to $49.00 in a research report on Tuesday, December 5th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $45.00.

Integra LifeSciences Price Performance

IART traded up $0.62 during trading on Friday, reaching $35.45. The stock had a trading volume of 823,648 shares, compared to its average volume of 854,022. The stock has a market cap of $2.79 billion, a PE ratio of 42.71, a PEG ratio of 1.05 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences Holdings Co. has a one year low of $33.24 and a one year high of $59.33. The business has a 50-day moving average of $39.49 and a 200-day moving average of $39.70.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The firm had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm’s revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.94 EPS. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.